University of Rhode Island

DigitalCommons@URI
Senior Honors Projects

Honors Program at the University of Rhode
Island

5-2009

Exploring the scientist-practitioner model in clinical psychology
Jami Halpern
University of Rhode Island, jlhalp@aol.com

Follow this and additional works at: https://digitalcommons.uri.edu/srhonorsprog
Part of the Social and Behavioral Sciences Commons

Recommended Citation
Halpern, Jami, "Exploring the scientist-practitioner model in clinical psychology" (2009). Senior Honors
Projects. Paper 126.
https://digitalcommons.uri.edu/srhonorsprog/126https://digitalcommons.uri.edu/srhonorsprog/126

This Article is brought to you for free and open access by the Honors Program at the University of Rhode Island at
DigitalCommons@URI. It has been accepted for inclusion in Senior Honors Projects by an authorized administrator
of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

EXPLORING THE SCIENTIST-PRACTITIONER MODEL
IN CLINICAL PSYCHOLOGY

BY

JAMI HALPERN
(W. GRANT WILLIS, FACULTY SPONSOR)

PAPER SUBMITTED IN PARTIAL FULFILLMENT OF
SENIOR HONORS PROJECT

UNIVERSITY OF RHODE ISLAND
2009

Exploring the Scientist Practitioner Model

1

Abstract
The Scientist-Practitioner Model is a system of education used by many
graduate programs in applied fields of psychology. The goal of this educational
model is to help clinicians and other practitioners to learn to use empirical
research as a basis for the applied work that they do and also for them to learn to
use the experience of applied clinical practice to guide research questions and to
advance scientific thinking in the discipline of Psychology. As a student who
plans to pursue a Ph.D. in Clinical Psychology, I felt that it would be beneficial
for me to experience the Scientist-Practitioner Model to gain a better understand
of what it entails.
In order to accomplish this goal, I have been participating in an internship
as a mental-health assistant in a group home for adult males. All of the residents
in this facility are afflicted with various psychiatric disorders; some experience
concomitant mild intellectual deficiencies and substance-abuse problems as well.
Outside of my internship, I have been investigating the topic of
Schizophrenia, a diagnosis that is common among many of the residents with
whom I am working. I am studying the epidemiological features of this disorder
and its etiology, course, treatment and management, and prognosis. By
synthesizing this information with my direct experiences in working in the group
home, I am developing researchable hypotheses about this disorder that ultimately
can be empirically tested. Thus, I am able to directly experience the Scientist-
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Practitioner Model, an exercise that I hope will help to better prepare me for my
future graduate school experiences.
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Exploring the Scientist-Practitioner Model in Clinical Psychology

The scientist-practitioner model of education is a major program
philosophy that forms the basis of many graduate programs in Clinical
Psychology. This model is used to help graduate students to learn how to
integrate science with applied practice, that is, to participate in the process
whereby science informs clinical practice and how clinical practice generates
empirical research. In the following literature review, the topic of Schizophrenia
is discussed. An historical background of the disorder is given and the origins of
its name are described. The DSM-IV-TR system of diagnosis is explained, a
description of the subtypes of Schizophrenia is provided, and their classifications
are explained. The course and prognosis of the disorder are then explained. Next,
the literature review identifies different theories of the etiology of the disorder,
including genetic and environmental explanations. Neurological theories are also
explained, including the dopamine theory, serotonin theory, glutamate theory,
cavum septum pellucidi theory, and ventricle theory. The literature review
concludes with information about how Schizophrenia is managed with
antipsychotic drugs and the possible side affects of those medications.
Next, a description of clinical experiences from an internship as a mentalhealth assistant is provided. It explains different symptoms experienced by clients
at a group home in Rhode Island. None of the information included in this section
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contains any identifying information; residents' ages have been generalized to a
range and no names have been included.
The final section includes different types of researchable hypotheses.
These questions were developed using the scientist-practitioner model. Here,
experiences gained through my clinical work led to particular questions about
Schizophrenia. The questions that were developed could possibly be used in
conducting a research study in the future.
Review of Literature
Schizophrenia is a psychotic disorder that, when diagnosed, comes with a
stigma attached to it. Many practitioners are reluctant to diagnose this disorder
because of this and the fact that it is a difficult diagnosis to make due to the broad
array of symptoms. Symptoms of the illness can be both positive and negative.
Positive symptoms include those that can be treated with medications, such as
hallucinations and delusions. Negative symptoms are those that are extremely
hard to treat such as flat or blunted affect.
Historical Issues
Emil Kraeplin was the first person to devise a way to classify psychosis
(Taylor, 2006). The first group of psychoses was dementia praecox, which means
“senility of the young.” This included “hebephrenia (a kind of childish insanity),
catatonia, and dementia paranoids (paranoia), and was said to follow a chronic
course” (Taylor, 2006, p. 3). The other classification was manic-depressive
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insanity (Taylor, 2006). Dementia praecox eventually became named
“Schizophrenia” in 1911 by Eugen Bleuler because the meaning of dementia
praecox was inaccurate. Regardless of the name used to label this psychiatric
disorder, it has been agreed upon that there is a biological aspect to it. Today, the
most common term for this disorder is Schizophrenia, but people must keep in
mind that a psychiatric disorder does not define the individual who has it. The
individual is a person first, and afflicted with Schizophrenia second. Thinking of
the disorder this way can help to reduce the stigma associated with it.
Throughout history, different individuals have classified Schizophrenia
with similar symptoms. Freud explained the main symptoms of Schizophrenia as
“thought disorder, blunting of affect (i.e. near-absent expressions of glee or
sadness) and autism (essentially social withdrawal). Hallucinations and delusions
were considered not as core symptoms but as reactions to the disease itself”
(Taylor, 2006, p. 3). Schneider’s first rank criteria were used by most
psychiatrists in Europe, and consisted of auditory hallucinations, thought insertion
or withdrawal, thought broadcasting, passivity feelings, and primary delusions
(Taylor, 2006). Other psychiatrists all over the world had different definitions of
what Schizophrenia was. This showed that there was a need for a classification
system.
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Classification and Subtypes
There are multiple classification systems for Schizophrenia, but all use
similar descriptions. The Diagnostic and Statistical Manual-IV-TR (APA, 2000),
which is the most common classification system used, uses the following criteria:

A disorder that lasts for at least 6 months and includes at
least 1 month of active-phase symptoms (i.e., two or more
of the following to be present for a significant portion of a
one month period: delusions, hallucinations, disorganized
speech, grossly disorganized or catatonic behavior,
negative symptoms (p. 298). There must be
Social/Occupational dysfunction, disturbance must persist
for at least six months, Schizoaffective and mood disorder
exclusion, substance/general medical condition exclusion,
and relationship to a pervasive developmental disorder. If
delusions are considered bizarre, then a diagnosis of
Schizophrenia is appropriate without any other symptoms.
The prevalence of Schizophrenia ranges from .05% to 1.5%
among adults and the “annual incidences are most often in
the range of 0.5 to 5.0 per 10,000” (p. 308). “Median age
of onset for the first psychotic episode of Schizophrenia is
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in the early to mid-20s for men and in the late 20s for
women” (p. 308). “Rates of comorbidity with SubstanceRelated Disorders are high. Nicotine Dependence is
especially high, with estimates ranging from 80% to 90%
of individuals with Schizophrenia being regular cigarette
smokers” (p. 304).

Schizophrenia is divided into different subtypes including paranoid type,
disorganized type, catatonic type, undifferentiated type, and residual type.
Paranoid type is “the presence of prominent delusions or auditory hallucinations
in the context of a relative preservation of cognitive functioning and affect”
(APA, 2000, p. 313). Disorganized type is defined as “prominent disorganized
speech, disorganized behavior, and flat or inappropriate behavior” (APA, 2000, p.
314). Catatonic type is “marked psychomotor disturbance that may involve
motoric immobility, excessive motor activity, extreme negativism, mutism,
peculiarities of voluntary movement, echolalia, or echopraxis” (APA, 2000, p.
315. Undifferentiated type is “the presence of symptoms that meet Criterion A of
Schizophrenia but that do not meet criteria for the Paranoid, Disorganized or
Catatonic type” (APA, 2000, p. 317). Residual type is used “when there has been
at least one episode of Schizophrenia, but the current clinical picture is without
prominent positive psychotic symptoms” (APA, 2000, p. 317). Schizophrenia is
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not a homogeneous psychiatric disorder. There are no two cases that are exactly
alike. The classification systems are extremely broad and two individuals with
completely different symptoms may end up with the exact same diagnosis.
Course and Prognosis
Schizophrenia is generally diagnosed during early adulthood and tends to
affect an individual for the rest of his or her life. It is rare to see only one
psychotic episode and then no symptoms following that episode. According to
Taylor (2006), “most cases of Schizophrenia are said to follow one of seven
patterns, which can be condensed into three broad outcomes: (1) continuous
course (no relapses or remissions); (2) undulating course (relapses with or without
residual symptoms in remissions); and (3) atypical course (various types but
including long-term improvement after continuous course)” (p. 8).
This disorder, however, can be managed with different types of
treatments. These treatments include the use of antipsychotic drugs. In the past,
antipsychotic drugs had many side affects similar to those of sedatives. Today,
pharmacology has come a long way to produce drugs that allow people to lead as
normal lives as possible. This is a huge step for individuals with Schizophrenia
because this gives them the opportunity to make a life for themselves if possible.
Today there are many different types of antipsychotic drugs, and the combinations
of drugs used differ on a case to case basis.
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Etiology
It is not completely clear as to what actually causes Schizophrenia. Some
researchers suggest that complications during pregnancy or birth can affect the
probability of becoming diagnosed with Schizophrenia in the future. There has
been a higher correlation between people being born in winter months and
becoming diagnosed with Schizophrenia as opposed to those who are born in the
summer months. This is thought to be a result of illness of the mother during
pregnancy (Taylor, 2006). Genetics are said to be a major reason for the
development of Schizophrenia. “The lifetime risk of Schizophrenia is around 1%;
in people born to parents who both have a diagnosis of Schizophrenia the lifetime
risk approaches 50%” (p. 14), and it is more common to see both identical twins
with Schizophrenia than to see both fraternal twins with Schizophrenia (Taylor,
2006). These differences are extreme, giving researchers evidence to support a
genetic theory.
Environment may also play a role in the development of Schizophrenia.
According to Taylor (2006), environmental factors are likely to play a role in the
development and progression of this illness and it has been determined that “60%
of all those diagnosed with Schizophrenia have no first or second-degree relatives
with the condition” (p. 14).
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There are many different theories behind schizophrenia and the brains
involvement with the illness. One theory is the dopamine theory, which “suggests
that the positive symptoms of schizophrenia are caused by overactivity of
synapses between dopaminergic neurons of the ventral tegmental area and
neurons in the nucleus accumbens and amygdala” (Carlson, 2007, p. 554). One of
the first drugs discovered that helps dramatically in the treatment of
Schizophrenia is chlorpromazine. It significantly decreased positive symptoms in
patients with Schizophrenia and it decreased the amount of time spent in hospitals
for patients with this illness (Carlson, 2007). Many drugs have since been
developed, all of which block dopamine receptors also known as dopamine
antagonists. Drugs that are dopamine agonists support this dopamine theory of
Schizophrenia as well. When individuals participate in the use of drugs such as
amphetamines, cocaine, methylphenidate (all block dopamine reuptake), and LDOPA (produces more dopamine), symptoms can occur which mimic those
psychotic symptoms of Schizophrenia and these symptoms produced by these
drugs can be relieved with antipsychotic drugs (Carlson, 2007). While the
dopamine theory does explain the positive symptoms of Schizophrenia, it does not
explain the negative symptoms which present similar to those of brain damage
(Carlson, 2007).
Some evidence against the dopamine theory is the failure of antipsychotics
that are dopamine antagonists (Taylor, 2006). The success of clozapine works
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against the dopamine theory because it has low dopamine receptor occupancy and
this suggests that there might be other transmitters in the brain involved in
schizophrenia (Williamson, 2006). Even though clozapine does work against the
dopamine theory because it is a low dopamine receptor, it does not work
completely against it because it is still somewhat of a dopamine antagonist. All
anti-psychotics that are currently prescribed are some sort of a dopamine
antagonist (Taylor, 2006). However, anti-psychotics that are D2 receptor
antagonists show the most support for the dopamine theory (Taylor, 2006).
It is thought that the serotonergic system might also be involved in
schizophrenia, specifically the 5HT2A receptor and most of the newer antipsychotics have 5HT2A antagonist activity (Taylor, 2006). This theory might
explain why clozapine, ziprasidone, risperidone, quetiapine, and olanzapine are
successful in the treatment of schizophrenia (Meltzer, et al., 2003), however
serotonin is closely related to dopamine which could also support the reasons for
clozapine’s success (Taylor, 2006). Serotonin agonists, along with dopamine
agonists, can cause psychotic symptoms and this supports both the serotonin and
dopamine theories of schizophrenia.
Glutamate, an amino acid, may also play a role in schizophrenia.
Glutamate “appears both to stimulate and inhibit dopamine release, depending on
the conditions and location. Cerebrospinal fluid glutamate levels may be altered
in people with schizophrenia (Taylor, 2006 p. 25).” The glutamate theory was
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based off a clinical observation of chronic abusers of NMDA receptor antagonist
phencyclidine (PCP) (Paz, et al., 2008). Dopamine, serotonin, and glutamate are
included in the major theories behind schizophrenia and the role that the brain
plays in the illness.
“An increased incidence of large cavum septum pellucidi has been
demonstrated in individuals with Schizophrenia. This may have important
pathophysiological implication, because it is suggestive of an early (i.e. prenatal)
midline developmental brain abnormality , at least in a subgroup of individuals
with schizophrenia” (APA, 2000, p. 305). Septum pellucidi is located underneath
the corpus callosum and “It is believed to be a relay station in the limbic system
connecting the hypothalamic autonomic system to hippocampus, amygdala,
habenula and brain-stem reticular formation” (Rajarethinam, et al., 2008, p. 22).
There is sometimes a cavity between the septum pellucidi and this is called the
cavum septum pellucidi, which is filled with cerebrospinal fluid and is sometimes
referred to as the 5th ventricle. This is present at birth in all humans; however it
does close up by the age of 3 in most people. It has been observed that this is
present in individuals with schizophrenia, supporting a biological reason for
causes of Schizophrenia.
More neurological evidence for the causes of Schizophrenia is loss of
brain tissue and enlarged ventricles in the brain. “In the Structural neuroimaging
literature, the most widely studied and most consistently replicated finding
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continues to be enlargement of the lateral ventricles” (APA, 2000, p. 305).
“Many studies have also demonstrated decreased brain tissue as evidence by
widened cortical sulci and decreased volumes of gay and white matter” (APA,
2000, p. 305). Ventricles are spaces deep within the brain and if the spaces are
larger than in a normal brain, then the mass of the actual tissue in the brain has to
be less in patients with Schizophrenia. “In fact, Hulshoff-Pol et al. (2002), foud
that although every one loses some cerebral gray matter as they age, the rate of
tissue loss is greater in schizophrenic patients” (Carlson, 2007).
Pharmacological Management
Antipsychotics are defined as “drugs used in the treatment of psychotic
disorders that help alleviate hallucinations and delusional thinking” (Nevid, 2009,
p. 582). There are many different types of antipsychotic drugs which fall into the
two categories of typical antipsychotic drugs and atypical antipsychotic drugs.
Typical antipsychotic drugs are older medications that tend to have more side
effects than atypical antipsychotic drugs. “The first class of antipsychotic drugs
were phenothiazines, which included the drugs Thorazine (chlorpromazine) and
Mellaril (thioridazine)” (Nevid, 2009, p. 582). These typical antipsychotics also
include Trifluoperazine (stelazine), Fluphenazine (Prolisin) and others, whose
side effects include “movement disorders, drowsiness, restlessness, dry mouth,
blurred vision, and muscle rigidity” (Nevid, 2009, p. 585). These drugs surfaced
in the 1950’s and were the first step in controlling hallucinations and delusions.
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Today, however, Mellaril (thioridazine) is “indicated for the management of
schizophrenic patients who fail to respond adequately to treatment with other
antipsychotic drugs. Due to the risk of significant, potentially life threatening,
proarrhythmic effects with thioridazine treatment, thioridazine should be used
only in patients who have failed to respond adequately to treatment with
appropriate courses of other antipsychotic drugs, either because of insufficient
effectiveness or the inability to achieve an effective dose use to intolerable
adverse effects form those drugs” (Physicians desk reference, 2009, p. 2195-6).
This is common to see with older medications. The newer atypical antipsychotic
drugs include clozapine, risperidone, olanzapine and others. These newer drugs
are just as effective as the previous typical antipsychotic drugs but tend to have
fewer side effects. However, there are still concerns for side effects with the
newer antipsychotic drugs. For example, the side effects of clozapine (clozaril)
can include “potentially lethal blood disorder, seizures, fast heart rate, drowsiness,
dizziness, nausea” (Nevid, 2009, p. 585). These side effects should be monitored
closely.
A major possible side effect of older typical antipsychotic drugs is tardive
dyskinesia. “Tardive dyskinesia (TD) is a painful and disfiguring motor side
effect of long-term anti-psychotic use. TD presents months or years after initiation
of anti-psychotic treatment, persists after drug withdrawal and may be irreversible
(Bishnoi, et al., 2008).” Symptoms of tardive dyskinesia present themselves very
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similarly to Parkinson’s disease, leading researchers to suspect that Schizophrenia
is the opposite of Parkinson’s disease. Antipsychotic drugs taken for the
treatment of Schizophrenia cause symptoms of Parkinson’s disease, and L-DOPA
taken in the treatment of Parkinson’s disease causes psychotic symptoms present
in Schizophrenia (Carlson, 2007). Atypical anti-psychotic drugs have less of a
chance of causing tardive dyskinesia than do the older typical anti-psychotic
drugs.
Applied Clinical Experience
For the past semester, I have been serving an internship as a MentalHealth Assistant at a group home in Rhode Island. All of the clients who live in
the home are men over the age of 18 and have been diagnosed with severe
psychiatric disorders; many also have substance-abuse problems and intellectual
disabilities. Through my clinical experience, I have had the opportunity to
observe the effects of mental disorders, the courses of those disorders, and how
they affect the individuals afflicted with them.
There have been many hospitalizations of the clients during my time at the
group home. Sometimes the hospitalizations are a result of medication refusals.
Most of the clients are overweight and some have diabetes. Many of the weightgain issues for the clients are a result of the medications that they are taking. For
example, Clozaril (a drug used in the management of Schizophrenia) often leads
to extreme weight gain. If insulin is not taken within a 24 hour time period, then
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hospitalization may be required. Hospitalization also is required if staff members
feel threatened by a client or if a client discloses that he is afraid of hurting
himself or someone else.
I have seen that it is hard to motivate the clients to exercise and to eat
healthy diets. Although the meals that are cooked for them are part of a balanced
diet, clients are free to spend their money on what they choose, and much of their
money is spent on junk food. The clients also have trouble with completing oraland physical-hygiene tasks. Many of them do not shower on a regular basis.
Almost all of the clients at the group home smoke cigarettes and have a
history of some sort of substance abuse. I have found that substance-abuse
problems are common among individuals with Schizophrenia; however, research
has not determined if the substance use is a result of the symptoms or if the illness
can be caused from substance use possibly as a part of a diathesis-stress model.
Client Examples
When I first started my internship, I had the opportunity to see how the
group home receives new clients. A new client in his early 20s was coming to
live at the home during the first month that I was there. When he arrived, I went
with him and his counselor to an intake meeting with the social worker. She
asked him about his background, but this client had difficulty reporting accurately
on his history. I was able to see that getting information from clients can be
difficult at times. The social worker asked him to describe his symptoms. This
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particular client is diagnosed with both Schizophrenia and an intellectual
disability. He reports that he hears multiple voices that argue with each other and
himself. He tries to negotiate with the voices in order to calm them down, but that
has not been effective. One of the voices dominates the others and commands
him to engage in activities in order to avoid harm or death. Recently, he has had a
medication change for psychoses. This same medication has helped other clients
in the group home as well, and it has helped to calm the voices that this client
reports hearing. In the past, no medications had worked to calm the voices so this
has been a marked improvement for this client. Already, I have noticed that it is
much easier to have a conversation with him and that he is able to better follow
the conversation and not go off on tangents.
Another client has given me the opportunity to see how the illness spirals
up and down. This client is an older male in his late 60s. When I first came to the
home, he was quiet and didn’t speak much. During the past three months,
however, he has been on a spiral downward into another cycle of Schizophrenia.
His voice has become high pitched and giddy; he tends to giggle a lot. He is
hypersexual and can often be found talking to an imaginary person. This appears
to be a hallucination. He also has grandiose delusions and paranoia.
Common Symptoms
Paranoia tends to be a common symptom among the clients who live in
the house. Some of the clients believe that people or the members of the Central
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Intelligence Agency (CIA) are pursuing them or that the people in the cars driving
by are inserting their thoughts into the client’s heads. Many of the clients also
tend to fixate on objects or possessions, for example, their money and their money
ledgers. Clients often ask their counselors to review their ledgers and budgets
with them. One day, I observed a client ask the counselor about his ledger over
five times.
Flat affect is a negative symptom of Schizophrenia that is hard to
understand until one has a chance to observe it. Some of the clients have this
negative symptom and show barely any emotion. It is rare to see these
individuals laugh or even smile, and they react to everything in the same manner.
Another client, in his 40s, appears to be depressed and bored with his life.
I think this is common among many of the clients because living in the group
home there is not too much excitement. Every day seems to be almost identically
scheduled, unless there is a doctor’s appointment or a different type of
appointment. This client tries to capture the attention of the counselors in the
house for his own entertainment. For example, he might refuse medication, start
arguments, and refuse to go to activities or day programs. I think that this is
because there is no change in his day to day life and he is bored and depressed
with his living situation. He frequently threatens to move out to see how the
counselors will react to his threats. If his threats are ignored by the counselors,
however, he tends to let them go.
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Researchable Hypotheses
After my experience at the group home and researching Schizophrenia I
have come up with some researchable hypotheses. I am curious as to why so
many people with Schizophrenia smoke cigarettes. Almost all of the clients at the
group home smoke at least a pack of cigarettes a day; according to the literature
on Schizophrenia my observation has been supported by the DSM-IV-TR (APA,
2000) that concludes that 80-90% of individuals with Schizophrenia smoke
cigarettes. I would like to look at whether these individuals with the disorder
smoke because of a reaction with their symptoms and, specifically, whether
smoking calms the symptoms (e.g., auditory hallucinations) of the disorder.
I have also noticed through my internship that individuals with
Schizophrenia tend to have a history of substance abuse. I would like to look at
whether people with the disorder use drugs because of their symptoms or if drug
use is part of a diathesis-stress model responsible for causing Schizophrenia.
Last, but not least, I would like to look at why so many individuals with
Schizophrenia have multiple diagnoses, for example Substance Abuse Disorder,
Intellectual Disability, and Depression.
Conclusion
This project has been an amazing experience. It has given me the
opportunity to experience the scientist-practitioner model and to realize that I
have chosen the right education path, being that I want to pursue a Ph.D. in
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Clinical Psychology. Interning at the group home has given me a chance to see
which mental disorders spark my interest. I have learned that Schizophrenia and
Substance Abuse are two areas that are of high interest to me.
Some limitations of the project include the short period of time that it had
to be completed in (one semester) and the amount of time spent at the group
home. If someone were to repeat this project, I would recommend that it should
be done over a full year period and that they should spend more than eight hours a
week at the facility. Over all, I am extremely thankful for having the opportunity
to complete a project of this type. Without this project I would have no clinical
experience that let me know that I have chosen the correct career path for me.
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